Until ImmunoGen (NASDAQ: IMGN) gets its lead drug, mirvetuximab soravtansine, on the market, quarterly earnings reports will be relatively uneventful.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,